Genetic Technologies Announces up to 6 New Breast Centres to Begin Offering BREVAGenplus(R)
January 29, 2015 05:30 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - Jan 29, 2015) - Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company") is pleased to report that up to 6 new breast...
Genetic Technologies Secures A$24 Million Standby Equity Placement Facility
January 21, 2015 18:27 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - Jan 21, 2015) - Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Genetic Technologies" or the "Company") today announced...
Clinical Validation Study Supporting the Use of BREVAGenplus(R) in Breast Cancer Risk Assessment
December 17, 2014 05:30 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - Dec 17, 2014) - Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company") announces that findings from a new research...
Neuren's NNZ-2566 Successful in Demonstrating Clinical Benefit in Rett Syndrome Phase 2 Trial
November 12, 2014 13:24 ET
|
Neuren Pharmaceuticals
BETHESDA, MD--(Marketwired - Nov 12, 2014) - Highlights:
Achieved primary endpoint -- both dose levels of NNZ-2566 were well tolerated after 28 days of treatment and...
Alchemia Announces Departure of Chief Executive Officer
November 10, 2014 17:13 ET
|
Alchemia
BRISBANE, AUSTRALIA--(Marketwired - Nov 10, 2014) - Alchemia Limited, (ASX: ACL) a drug discovery and development company, today announced the departure of Thomas Liquard as Chief Executive...
Alchemia Announces Phase III Trial Results for HA-Irinotecan in Metastatic Colorectal Cancer
October 26, 2014 18:28 ET
|
Alchemia
BRISBANE, AUSTRALIA--(Marketwired - Oct 26, 2014) - Alchemia Limited (ASX: ACL)
Summary:
Phase III trial does not reach primary endpoint of statistically...
Alchemia Announces Database Lock of Its HA-Irinotecan Pivotal Phase III Trial in Metastatic Colorectal Cancer
October 09, 2014 20:12 ET
|
Alchemia
BRISBANE, AUSTRALIA--(Marketwired - Oct 9, 2014) - Alchemia Limited (ASX: ACL)
Database lock triggers commencement of primary endpoint analysis
350...
Genetic Technologies Announces Quarterly BREVAGen(TM) Results
October 06, 2014 05:30 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - Oct 6, 2014) - Molecular diagnostics (MDx) company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company") reported 942 BREVAGen™ test samples...
Genetic Technologies Launches BREVAGenplus(R) Breast Cancer Risk Assessment Test
October 01, 2014 05:30 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - Oct 1, 2014) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" ) is pleased to announce the US launch of BREVAGenplus, an easy-to-use...
Genetic Technologies Announces Appointment of Independent Non-Executive Directors
September 24, 2014 05:30 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - Sep 24, 2014) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company") is pleased to advise that Mr. David Carter and Dr. Lindsay Wakefield have...